Dublin, June 17, 2022 (GLOBE NEWSWIRE) -- The "Rapid Diagnostics Market by Product (Kits [OTC, Professional], Readers), Platform (Lateral Flow, Serological, PCR), Application (Blood Glucose, Infectious Diseases, Pregnancy, Drugs of Abuse), End User (Hospitals, Diagnostic Labs, Home Care) - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global rapid diagnostics market is expected to grow at a CAGR of 1.4% from 2022-2029 to reach $26.40 billion by 2029. The growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, and emerging technological innovations are the key factors driving the growth of the global rapid diagnostics market. Further, the rising market potential in emerging economies, such as China and India, provides significant opportunities for existing market players and new entrants. The rising number of people suffering from non-communicable and infectious diseases, the growing population, and the rising urbanization are expected to provide significant growth opportunities in this region. Based on product, the test readers/analyzers segment is expected to witness the fastest growth rate during the forecast period. The high growth rate of this segment is attributed to the capabilities of these devices to simultaneously read multiple tests in one scan and scale large volumes. In addition, healthcare facilities adopt analyzers for quick analysis compared to centralized lab analyzers due to their features, such as compact size, portability, and easy accessibility. Based on platform, the molecular detection segment is expected to witness the fastest growth rate during the forecast period. The growth of this segment is attributed to the increasing popularity and awareness of molecular detection tests and the high demand for rapid PCR diagnostic kits due to the COVID-19 pandemic.

For instance, according to google trends, the popularity and awareness of RT-PCR diagnostic tests in developing economies, such as India, the Philippines, and Brazil, have increased significantly recently due to the high demand for RT-PCR diagnostic kits for COVID-19 infection diagnosis. Also, various companies have launched PCR kits for qualitative and quantitative detection of COVID-19 infections.

Some of the examples include:

In February 2021, Bio-Rad Laboratories, Inc. (U.S.) launched the reliance SARS-CoV-2/FluA/FluB RT-PCR assay kit.

In February 2021, Thermo Fisher Scientific Inc. (U.S.) launched the TaqPath COVID-19 RT-PCR Kit.

In December 2020, F. Hoffmann-La Roche Ltd (Switzerland) launched the Elecsys SARS-CoV-2 Antigen test, a rapid detection test for diagnosing active COVID-19 infections.

Based on application, the tumor/cancer markers testing segment is expected to witness the fastest growth rate during the forecast period. The rising incidences of cancer amongst the general population is the major factor attributed to the growth of this segment. According to WHO, cancer was the leading cause of death globally in 2020, accounting for approximately 10 million deaths. Furthermore, nearly 70% of deaths out of the total deaths from cancer occur in low- and middle-income countries; therefore, early detection is extremely important to reduce mortality, enhance survival, and save treatment costs. Thus, healthcare workers utilize various rapid diagnostic kits for the early detection of cancer. Based on end user, the hospitals & clinics segment is expected to show the fastest growth rate during the forecast period. The large share of this segment is mainly attributed to the increasing demand for point-of-care diagnostics and the increasing healthcare expenditure worldwide, driving the demand for rapid diagnostic kits used in hospitals & clinics.

Furthermore, the outbreak of the COVID-19 pandemic resulted in the increased demand for rapid diagnostic kits in hospitals & clinics for the treatment and prevention of COVID-19 infections. North America is expected to account for the largest share of the global rapid diagnostics market in 2022, followed by Asia-Pacific and Europe.

Rising Prevalence of Chronic Diseases Coupled with the Increasing Geriatric Population

Growing Prevalence of Infectious Diseases

Increasing Need for Rapid Decision-Making

Growing Demand for Point-of-Care (POC) Diagnostics

Reluctance Toward Changing Existing Diagnostic Practices

The Impact of COVID-19 on the Rapid Diagnostics Market

Rapid Diagnostics: Innovations & Upcoming Technologies

Company Profiles (Business Overview, Financial Overview, Products Portfolio, Strategic Developments)

Dickinson and Company (U.S.)

Bio-Rad Laboratories Inc. (U.S.)

F. Hoffmann-La Roche Ltd. (Switzerland)

ACON Laboratories Inc. (U.S.)

Thermo Fisher Scientific Inc. (U.S.)

Alfa Scientific Designs Inc. (U.S.)

Meridian Bioscience Inc. (U.S.)

Rapid Diagnostics Market, by Product

Rapid Diagnostics Market, by Platform

Rapid Diagnostics Market, by Application

Sexually Transmitted Diseases (STD) Testing

Healthcare Associated Infection (HAI) Testing

Rapid Diagnostics Market, by End User

For more information about this report visit https://www.researchandmarkets.com/r/f4byd6

Though the United States appears to be coming out of the worst of the pandemic, COVID-19 isn't going away any time soon. And there remains the continued risk of another surge as more states relax...

Here's how to know if you are at risk of Long COVID following an infection and specific lingering symptoms that you should discuss with your doctor.

COVID-19 is surging again nationwide, driven by even more contagious new variants. In five states, the virus has begun spreading exponentially in recent weeks. But health experts in those states have related insights about the latest virus variants and advice on staying safe that's useful no matter where you live. Read on to find out more—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 Wyoming According to the New York Times' coronaviru

You may know that there are links between the foods and drinks you consume and different kinds of cancers.For instance, red meat has been linked with higher colorectal cancer risk, and alcoholic beverages have been connected to higher risk of breast cancer, while cauliflower could help lower your chance of getting liver cancer.Now, new research suggests that eating more fish is linked with a higher risk of melanoma.In the study, published earlier this month in the journal Cancer Causes&Control,

A pediatric critical care physician said she continues to see young patients being admitted to the hospital after they tried a dangerous stunt or challenge they saw on TikTok.

Story at a glance Poor diet can lead to a variety of health issues including high blood pressure, obesity, and certain cancers. Social determinants of health, including the high cost of healthy food, can hinder widespread efforts to improve Americans’ nutrition habits. New preliminary research from The American Society of Nutrition found the vast majority…

Millions of U.S. children between the ages of 6 months and 4 years will soon be eligible for COVID-19 shots. FatCamera/E+ via Getty ImagesFor many parents of kids under age 5, a safe and effective COVID-19 vaccine could not come soon enough. A full year and a half after shots first became available for adults, their wait is nearly over. On June 17, 2022, the Food and Drug Administration authorized both the Pfizer-BioNTech and Moderna COVID-19 shots for the nearly 20 million U.S. children between

Following a sign-off from the country's top two health care agencies, children as young as 6 months old can now be vaccinated against Covid-19 — more than two years after adults were first able to get the shots. The U.S. Food and Drug Administration authorized the vaccines, which are made by Cambridge's Moderna Inc. (Nasdaq: MRNA) and New York-based Pfizer Inc. (NYSE: PFE), on Friday following a unanimous recommendation from its advisory committee. The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices met on Friday and Saturday and also endorsed the shots.

The number of people with medical cannabis licenses in the U.S. rose to 2.97 million in 2020 from 678,408 in 2016, according to a study of state data

Syndax Pharmaceuticals has toiled for years toward finding cancer therapies that can improve the lives of patients.

(Reuters) -The U.S. Food and Drug Administration on Friday authorized two COVID-19 vaccines for children under 5, opening the door to vaccinating millions of the country's youngest children once the Centers for Disease Control and Prevention agrees. The FDA authorized Pfizer-BioNTech's COVID-19 vaccine for children aged 6 months to 4 years and Moderna Inc's shot for those 6 months to 17 years. Pfizer's is already authorized for those over the age of 5.

Story at a glance Wildfires are among the most devastating natural disasters, due in part to their tendency to recur in specific geographic areas. Aggravated by climate change, wildfires have become more frequent in recent decades, taking a toll on vulnerable rural communities and first responders alike. But improving access to mental health care and…

Is Pfizer stock a buy after the FDA signed off on its Covid vaccine for babies and toddlers? Is PFE stock a buy right now?

Fayette County remains at both a high transmission level and high COVID-19 community level, according to the latest update from the federal health agency. Here’s where the rest of the state stands.

Witthaya Prasongsin via GettyOne common symptom that people with autism struggle with is the inability to interpret facial expressions. This can lead to difficulty in reading social cues in their personal lives, school, workplace, and even media like movies and TV shows. However, researchers at MIT have created an AI that helped shed light on why exactly this is.A paper published on Wednesday in The Journal of Neuroscience unveiled research that found that neurotypical adults (those not displayi

All children 6 months and older are now eligible to receive the COVID-19 vaccine, the U.S. Centers for Disease Control and Prevention announced Saturday.

Every 36 seconds, someone dies of heart disease in the U.S., accounting for one in every four deaths of all causes, according to the Centers for Disease Control (CDC). That's why it's so crucial to take care of your heart health by lowering your blood pressure, blood sugar, and cholesterol levels. Making changes to your diet can help you achieve these heart health benchmarks, lowering your risk of heart attack, stroke, aneurysm, and other acute threats. In particular, experts say one popular bev

The U.S. Food and Drug Administration has authorized use of the COVID-19 vaccines from Pfizer and BioNTech, and from Moderna, for kids between six months and five years of age. The FDA's decision follows a lengthy review process, and the dosage for children under five is greatly reduced relative to those for older children and adults. While Pfizer's vaccine was previously authorized in the U.S. for people five and up, Moderna's inoculation was limited to those aged 18 or above.

Infectious disease specialist Dr. Monica Gandhi says the challenges brought on by the Omicron variant highlight the need for new vaccines: ones that are longer-lasting, that can protect us against future variants, that stop transmission and offer protection against all symptoms, including mild ones.

A new drug called Olumiant could be hitting the market soon. The FDA has approved the drug for treating people with severe alopecia. Our guests share their experience with the disorder, and their thoughts on the new drug.